Satellos to commence Phase I trial for DMD drug

Canada-based Satellos Bioscience will be dosing the first patient in a Phase I trial of its Duchenne muscular dystrophy (DMD) drug after receiving a rare pediatric disease designation (RPDD) from the US Food and Drug Administration (FDA).